Literature DB >> 21803095

Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles.

N Hanumantha Rao1, P Baji Babu, L Rajendra, R Sriraman, Yuk-Ying S Pang, John T Schiller, V A Srinivasan.   

Abstract

The major capsid protein (L1) of human papillomaviruses (HPV) expressed in heterologous systems assembles into virus-like particles (VLPs). We report cloning and expression of codon optimized HPV L1 genes of the two high-risk HPV types 16 and 18 in methylotropic yeast, Pichia pastoris. The VLPs produced in P. pastoris were subjected to three step purification method involving density gradient centrifugations and size exclusion chromatography. The enriched VLPs were characterized using conformation-specific monoclonal antibodies in ELISA and by transmission electron microscopy. Mice immunized with a bivalent HPV16 and HPV18 VLPs developed high serum antibody titers to both HPV types that persisted for 190 days post vaccination. Serum of mice immunized with the HPV-VLP preparations could neutralize homologous pseudoviruses in an in vitro assays. Our results demonstrate that the L1 proteins expressed in P. pastoris fold properly as evidenced by assembly into VLPs and induction of type-specific neutralizing antibody response in mice. This work constitutes a step towards developing an alternate production platform for generating an affordable HPV vaccine to meet the needs of developing countries.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803095      PMCID: PMC3507537          DOI: 10.1016/j.vaccine.2011.07.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.

Authors:  J C Cook; J G Joyce; H A George; L D Schultz; W M Hurni; K U Jansen; R W Hepler; C Ip; R S Lowe; P M Keller; E D Lehman
Journal:  Protein Expr Purif       Date:  1999-12       Impact factor: 1.650

Review 2.  Delivering on the promise: HPV vaccines and cervical cancer.

Authors:  John T Schiller; Philip Davies
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

3.  The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.

Authors:  Darron R Brown; Suzanne M Garland; Daron G Ferris; Elmar Joura; Marc Steben; Margaret James; David Radley; Scott Vuocolo; Elizabeth I O Garner; Richard M Haupt; Janine T Bryan
Journal:  Hum Vaccin       Date:  2011-02-01

4.  Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi.

Authors:  A Varsani; A-L Williamson; R C Rose; M Jaffer; E P Rybicki
Journal:  Arch Virol       Date:  2003-09       Impact factor: 2.574

5.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

6.  Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles.

Authors:  J Zhou; X Y Sun; H Davies; L Crawford; D Park; I H Frazer
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

Review 7.  Classification of papillomaviruses.

Authors:  Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

Review 8.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 9.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality.

Authors:  F Xavier Bosch; Silvia de Sanjosé
Journal:  J Natl Cancer Inst Monogr       Date:  2003

10.  Production of human papillomavirus type 16 virus-like particles in transgenic plants.

Authors:  Sophia Biemelt; Uwe Sonnewald; Petra Galmbacher; Lothar Willmitzer; Martin Müller
Journal:  J Virol       Date:  2003-09       Impact factor: 6.549

View more
  7 in total

1.  HPV vaccines: Global perspectives.

Authors:  Gaurav Gupta; Reinhard Glueck; Pankaj R Patel
Journal:  Hum Vaccin Immunother       Date:  2017-03-31       Impact factor: 3.452

2.  Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs.

Authors:  P Vidyasagar; V N Sridevi; S Rajan; A Praveen; A Srikanth; G Abhinay; V Siva Kumar; R R Verma; L Rajendra
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

Review 3.  A review of clinical trials of human papillomavirus prophylactic vaccines.

Authors:  John T Schiller; Xavier Castellsagué; Suzanne M Garland
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

4.  Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.

Authors:  F C Mariz; E C Coimbra; A L S Jesus; L M Nascimento; F A G Torres; A C Freitas
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

5.  A VLP-Based Vaccine Candidate Protects Mice against Japanese Encephalitis Virus Infection.

Authors:  Limin Yang; Aibo Xiao; Hu Wang; Xiaojuan Zhang; Yuan Zhang; Yunlong Li; Yanqiu Wei; Wenjun Liu; Chuangfu Chen
Journal:  Vaccines (Basel)       Date:  2022-01-26

Review 6.  Recombinant vaccines in 2022: a perspective from the cell factory.

Authors:  Marianna Teixeira de Pinho Favaro; Jan Atienza-Garriga; Carlos Martínez-Torró; Eloi Parladé; Esther Vázquez; José Luis Corchero; Neus Ferrer-Miralles; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2022-10-05       Impact factor: 6.352

7.  N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.

Authors:  Minxi Wei; Daning Wang; Zhihai Li; Shuo Song; Xianglin Kong; Xiaobing Mo; Yurou Yang; Maozhou He; Zhongyi Li; Bo Huang; Zhijie Lin; Huirong Pan; Qingbing Zheng; Hai Yu; Ying Gu; Jun Zhang; Shaowei Li; Ningshao Xia
Journal:  Emerg Microbes Infect       Date:  2018-09-26       Impact factor: 7.163

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.